Langerhans histiocytosis in a child - diagnosed by oral manifestations.

J Clin Diagn Res

Professor and Head, Department of Pedodontics & Preventive Dentistry, Sri Rajiv Gandhi College of Dental Science and Hospital, Bengaluru, Karnataka, India .

Published: April 2015

Langerhans Histiocytosis (LCH) is a rare reactive and proliferative disease of histiocytes with unknown etiology, characterized by excessive proliferation of histiocytes called Langerhans cells. It occurs mainly in children but occurrence in adults has also been reported. It manifests as punched out lesions in the skull, maxilla, mandible, sternum and other flat bones and causes rapid resorption of the alveolar bone leading to floating teeth appearance in the radiographs. This disease manifests initially in the oral cavity in most of the cases and can be diagnosed by careful clinical and radiological examination. Here, we present a case of LCH in a child which was diagnosed by a swelling in the mandibular region.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437168PMC
http://dx.doi.org/10.7860/JCDR/2015/12353.5786DOI Listing

Publication Analysis

Top Keywords

langerhans histiocytosis
8
child diagnosed
8
histiocytosis child
4
diagnosed oral
4
oral manifestations
4
manifestations langerhans
4
histiocytosis lch
4
lch rare
4
rare reactive
4
reactive proliferative
4

Similar Publications

Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease.

Rheumatology (Oxford)

January 2025

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.

Objective: Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that exhibits a wide spectrum of clinical manifestations. The recent identification of activating mutations in the MAPK-ERK pathway in patients with ECD has led to the introduction of targeted therapies. The most commonly used targeted therapies are BRAF- and MEK-inhibitors, which are highly effective but also carry significant toxicity.

View Article and Find Full Text PDF

Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement.

Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses.

Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively.

View Article and Find Full Text PDF

Langerhans cell histiocytosis (LCH), juvenile xanthogranuloma (JXG) family lesions, and Rosai-Dorfman-Destombes disease (RDD) are now classified by the World Health Organization (WHO) under the heading of histiocytic/dendritic cell neoplasms. Each disease may manifest as a focal lesion, as multiple lesions, or as a widespread aggressive systemic disease with visceral organ involvement. Erdheim-Chester disease (ECD) is a rare systemic disease process of adults with limited cases in children.

View Article and Find Full Text PDF

A Childhood Langerhans Cell Histiocytosis With a Novel BRAFN486_T491delinsK Mutation: Good Response to Conventional Chemotherapy.

J Pediatr Hematol Oncol

January 2025

Department of Pediatrics, West China Second University Hospital, Sichuan University, Sichuan, China.

Langerhans cell histiocytosis (LCH) is characterized genetically by diverse gene mutations of the mitogen-activated protein kinase signaling cascade. BRAFN486_T491delinsK mutation is a rare mutation that involves the β2-αC ring domain, causing activation of the mitogen-activated protein kinase pathway, and is predicted to be resistant to the chemotherapy and BRAFV600E inhibitor in adult LCH cases. Here, we report a childhood LCH case with this novel BRAF mutation and had a good response to conventional chemotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!